Literature DB >> 29911822

At-a-glance - Lessons learned from launching the Manitoba Take-Home Naloxone Program.

Songul Bozat-Emre1,2, Shelley G Marshall3, Colin Zhong1,4, Joss Reimer1,2,3.   

Abstract

The Government of Manitoba launched the provincial Take-Home Naloxone Program in January 2017. By the end of September 2017, there were over 60 sites operating in Manitoba. These sites distributed 765 kits to people at risk of opioid overdose, and 93 of these kits were replacement kits used in overdose events. Most of these events occurred among males (60.2%) and in a private residence (72.0%). Fentanyl and carfentanil were the most common substances reported during overdose events. Take-Home Naloxone Program data provide important information about the unique context of the opioid crisis in Manitoba.

Entities:  

Keywords:  naloxone distribution; opioid; overdose response

Mesh:

Substances:

Year:  2018        PMID: 29911822      PMCID: PMC6034973          DOI: 10.24095/hpcdp.38.6.06

Source DB:  PubMed          Journal:  Health Promot Chronic Dis Prev Can        ISSN: 2368-738X            Impact factor:   3.240


  2 in total

1.  The fentanyl family: A distinguished medical history tainted by abuse.

Authors:  R B Raffa; J V Pergolizzi; J A LeQuang; R Taylor; S Colucci; M H Annabi
Journal:  J Clin Pharm Ther       Date:  2017-10-04       Impact factor: 2.512

Review 2.  A systematic review of community opioid overdose prevention and naloxone distribution programs.

Authors:  Angela K Clark; Christine M Wilder; Erin L Winstanley
Journal:  J Addict Med       Date:  2014 May-Jun       Impact factor: 3.702

  2 in total
  2 in total

1.  Commentary - Building the evidence base for sustained public health response to the opioid epidemic in Canada.

Authors:  Theresa Tam
Journal:  Health Promot Chronic Dis Prev Can       Date:  2018-06       Impact factor: 3.240

2.  Facilitators, barriers and lessons learnt from the first state-wide naloxone distribution conducted in West Virginia.

Authors:  Toni Marie Rudisill; Alexandria J Ashraf; Herbert I Linn; Sheena Sayres; James E Jeffries; Kelly K Gurka
Journal:  Inj Prev       Date:  2020-09-01       Impact factor: 3.770

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.